Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 12/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18319891 | 0.89 | KMT2A (0.39) | PTPN11PRNPPOLBKMT2ARXFP1 | |
| SCHEMBL22302407 | 0.86 | THRB (0.38) | PRNPPOLBKMT2ARXFP1GSTP1 | |
| SCHEMBL19785529 | 0.81 | KMT2A (0.35) | PTPN11PRNPPOLBKMT2ARXFP1 | |
| SCHEMBL18319553 | 0.78 | KMT2A (0.40) | PTPN11PRNPPOLBKMT2ARXFP1 | |
| SCHEMBL18319841 | 0.76 | KMT2A (0.45) | PRNPPOLBKMT2ARXFP1GSTP1 | |
| SCHEMBL29506060 | 0.76 | KMT2A (0.45) | PRNPPOLBKMT2ARXFP1GSTP1 | |
| SCHEMBL18320486 | 0.75 | KMT2A (0.44) | PRNPPOLBKMT2ARXFP1GSTP1 | |
| SCHEMBL29603922 | 0.75 | KMT2A (0.44) | PRNPPOLBKMT2ARXFP1GSTP1 | |
| SCHEMBL22303458 | 0.75 | KMT2A (0.42) | PTPN11PRNPPOLBKMT2ARXFP1 | |
| SCHEMBL28203390 | 0.75 | ALDH1A1 (0.40) | PTPN11PRNPKMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220251083-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-08-11 | — | — | US | disclosed |
| CN-113874363-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | PTPN11 24/4885PRNP 1522/4885POLB 2681/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PTPN11 24/4885PRNP 1522/4885POLB 2681/4885 |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PTPN11 24/4885PRNP 1522/4885POLB 2681/4885 |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | PTPN11 24/4885PRNP 1522/4885POLB 2681/4885 |
| US-20220251083-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PTPN11 24/4885PRNP 1522/4885POLB 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.